Today in Kyiv, UIPHP experts presented preliminary results of a study conducted by the Institute on the instruction of the Center for Public Health of the Ministry of Health of Ukraine.
The project "Evaluation of ART optimization at national level" was implemented in partnership with the International Center for Health Education and Training (I-TECH), US Centers for Disease Control and Prevention (CDC) and the Network “100% Life” (All-Ukrainian Network of PLHIV).
The study was conducted in 12 regions of Ukraine, it aimed to determine the attitude of HIV-infected patients, physicians and experts to the transition to new ART regimens - in particular, the treatment regimen with the drug Dolutegravir.
Patients receiving Dolutegravir showed greater adherence to treatment and noted an improvement in quality of life due to the absence or reduction of adverse effects.
Experts and healthcare providers arriveв at a conclusion that the implementation of ART optimization is successful and meets the needs of the country, and the attitude of the medical community to the strategy of ART optimization and the use of Dolutegravir as a first-line ART scheme is mainly positive.
By the end of 2019, about 42% of HIV-infected patients in Ukraine receive Dolutegravir.